UK highlights life sciences’ key role in post-COVID recovery
Building a better future for people with rare diseases in all four UK nations
Labour accuses government of cronyism in COVID-19 contracts
Who could influence the makeup of the new PPRS?
Hung parliament: who will pharma negotiate with on new PPRS?
The aims and implications of the Health Service Medical Supplies (Costs) Act 2017.
New UK law to control generic drug prices – implications for pharma